4.7 Article

AQP4 antibody-positive Thai cases Clinical features and diagnostic problems

期刊

NEUROLOGY
卷 77, 期 9, 页码 827-834

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31822c61b1

关键词

-

资金

  1. Siriraj Hospital [R015232060]
  2. KAKENHI of The Ministry of Education, Culture, Sports, Science and Technology of Japan [19209032, 20390241, 21790828, 22229008]
  3. Ministry of Health, Labour and Welfare of Japan
  4. Merck Serono
  5. Bayer Schering Pharma
  6. Eisai Inc.
  7. sanofi-aventis
  8. Biogen Idec
  9. Mitsubishi Tanabe Pharma Corporation
  10. Ministry of Education, Science and Technology
  11. Astellas Pharma Inc.
  12. Takeda Pharmaceutical Company Limited
  13. Asahi Kasei Kuraray Medical Co., Ltd.
  14. Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)
  15. Teva Pharmaceutical
  16. Teijin Pharma
  17. Kowa Pharmaceuticals America, Inc.
  18. Pfizer Inc
  19. Novartis
  20. Bayer Schering
  21. Grants-in-Aid for Scientific Research [19209032, 21790828, 20390241] Funding Source: KAKEN

向作者/读者索取更多资源

Objective: To evaluate the prevalence of aquaporin-4 (AQP4) antibody in Thai patients with idiopathic inflammatory demyelinating CNS diseases (IIDCDs) and to analyze the significance of the autoantibody to distinguish neuromyelitis optica (NMO) and other NMO spectrum disorders (ONMOSDs) from other IIDCDs, especially multiple sclerosis (MS). Methods: We retrospectively evaluated 135 consecutive patients with IIDCDs seen at the MS clinic at Siriraj Hospital, Bangkok, Thailand, and classified them into NMO, ONMOSDs, optic-spinal MS (OSMS), classic MS (CMS), and clinically isolated syndrome (CIS) groups in this order with accepted diagnostic criteria. The patients' coded sera were tested separately for AQP4 antibody. Then the relations between the clinical diagnosis and the AQP4 antibody serologic status were analyzed. Results: Among the 135 patients, 53 (39.3%) were AQP4 antibody-positive. Although the AQP4 antibody-positive group had features of NMO, such as female predominance, long cord lesions (>3 vertebral bodies), and CSF pleocytosis, only 18 patients (33% of 54) fully met Wingerchuk 2006 criteria except for AQP4 antibody-seropositive status. We also detected some AQP4 antibody-positive patients in the OSMS (4 of 7), CMS (11 of 46), and CIS (1 of 16) groups. These patients had been misdiagnosed with MS because they often had brain lesions and never underwent spinal cord MRI examination or lacked long cord lesions. Conclusions: AQP4 antibody was highly prevalent (almost 40%) in Thai patients with IIDCDs. Moreover, only one-third of AQP4 antibody-positive patients fully met Wingerchuk 2006 criteria, and many were misdiagnosed with MS. A sensitive AQP4 antibody assay is required in this region because the therapy for NMO is different from that for MS. Neurology (R) 2011;77:827-834

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据